Press Releases VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-30 pm EDT			5-day change	1st Jan Change
5.94 ^USD	+1.54%		+19.68%	-36.18%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

VACCINEXPAR : 12th Alzheimer’s & Parkinson’s Drug Development Summit Presentation	Apr. 26	PU
Vaccinex Reports 2023 Financial Results and Provides Corporate Update	Apr. 02	AQ
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	Mar. 27	AQ
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology	Feb. 21	AQ
Vaccinex, Inc. Announces Reverse Stock Split	Feb. 15	AQ
Vaccinex Announces Pricing of $3.7 Million PIPE Financing	Feb. 07	AQ
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule	Dec. 04	AQ
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 13	AQ
Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting	23-10-31	AQ
Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in and ongoing Phase 1/2 AD study	23-10-26	PU
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	23-10-26	AQ
Keystone Symposium: B cells and TLS_POSTER	23-10-04	PU
Vaccinex Announces Pricing of $9.6 Million Public Offering	23-09-28	AQ
Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration	23-09-28	AQ
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application	23-09-27	GL
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application	23-09-27	AQ
Vaccinex : DOT2023poster	23-09-26	PU
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	23-09-26	GL
Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	23-09-26	AQ
Vaccinex, Inc. Announces Reverse Stock Split	23-09-22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases VACCINEXPAR

Equities

VCNX

US9186403013

Press Releases

Filters